Good overall performance which confirms the relatively “inflation” immune position of the company. The unchanged guidance is positive but is unlikely to be a major catalyst for the stock.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good overall performance which confirms the relatively “inflation” immune position of the company. The unchanged guidance is positive but is unlikely to be a major catalyst for the stock.
